Company: CERO
Filing Date: 2025-06-06
Form Type: 424B3
Source: 0001213900-25-052185
Chunk: 6

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-06
Form: 424B3
Chunk 6
---
 Act (17 CFR 240.14a-12) |

| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |

| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

<div align='center'>Securities registered pursuant to Section 12(b) of the Act:</div>

| Title of each class                                                    |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, $0.0001 par value per share                              |     | CERO              |     | Nasdaq Capital Market                     |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | Nasdaq Capital Market                     |

Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

| Item 3.02 | Unregistered Sales of Equity Securities. |

As previously reported on the Current Report on Form
8-K filed with the Securities and Exchange Commission (the “SEC”) on April 22, 2025, CERo Therapeutics Holdings, Inc. (the
“Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional
investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in one or more closings, up to 10,000
shares of the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”),
which are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), in
a private placement offering.

On June 5, 2025, pursuant to the Securities Purchase
Agreement,